Subtopic Deep Dive

← Atherosclerosis and Cardiovascular Diseases

Oxidized LDL in Atherosclerosis
Research Guide

What is Oxidized LDL in Atherosclerosis?

Oxidized low-density lipoprotein (oxLDL) drives atherosclerosis by promoting macrophage uptake via scavenger receptors, leading to foam cell formation and plaque development.

OxLDL forms through oxidative modification of LDL in the arterial wall, recognized by scavenger receptors like CD36 and SR-A rather than the LDL receptor. Macrophages internalize oxLDL, becoming foam cells that initiate atherosclerotic lesions. Key studies include Witztum and Steinberg (1991, 2669 citations) establishing oxLDL's atherogenic role and Ylä-Herttuala et al. (1989, 1891 citations) detecting oxLDL in human and rabbit lesions.

Curated Papers

Key Challenges

Why It Matters

OxLDL uptake by macrophages via CD36 triggers foam cell formation, central to plaque initiation and progression, as shown in Febbraio et al. (2000, 1034 citations) where CD36 disruption reduced lesions in apoE-null mice. Myeloperoxidase from macrophages oxidizes LDL in lesions (Daugherty et al., 1994, 1282 citations), linking inflammation to oxidation. Therapeutic targeting of oxLDL pathways informs anti-atherosclerotic drugs, with Steinberg (1997, 1635 citations) detailing pathobiological significance.

Key Research Challenges

Mechanisms of LDL Oxidation

Identifying in vivo oxidation catalysts like myeloperoxidase remains challenging due to complex arterial environments. Daugherty et al. (1994) showed MPO expression in lesions generates reactive intermediates for LDL oxidation. Distinguishing minimal vs. extensive oxidation effects persists.

Scavenger Receptor Specificity

Determining contributions of CD36 vs. SR-A to oxLDL uptake in vivo is unresolved. Febbraio et al. (2000) found CD36-null mice protected against lesions, but overlapping functions complicate knockout studies. Quantifying receptor roles in human plaques needs advanced models.

Therapeutic Targeting Viability

Developing antioxidants or receptor blockers faces failures in clinical trials despite preclinical success. Witztum and Steinberg (1991) hypothesized oxLDL products affect multiple atherogenic steps, but translation to humans is limited. Inflammation-oxidation crosstalk, per Libby (2012), adds complexity.

Essential Papers

Inflammation in Atherosclerosis

Peter Libby · 2012 · Arteriosclerosis Thrombosis and Vascular Biology · 3.7K citations

Experimental work has elucidated molecular and cellular pathways of inflammation that promote atherosclerosis. Unraveling the roles of cytokines as inflammatory messengers provided a mechanism wher...

Atherosclerosis

Christopher K. Glass, Joseph L. Witztum · 2001 · Cell · 3.0K citations

Role of oxidized low density lipoprotein in atherogenesis.

Joseph L. Witztum, Daniel Steinberg · 1991 · Journal of Clinical Investigation · 2.7K citations

Evidence to support an important role of oxidative modification in mediating the atherogenicity of LDL continues to grow. New hypotheses suggest mechanisms by which Ox-LDL or products of Ox-LDL can...

Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.

Seppo Ylä‐Herttuala, Wulf Palinski, Michael E. Rosenfeld et al. · 1989 · Journal of Clinical Investigation · 1.9K citations

Three lines of evidence are presented that low density lipoproteins gently extracted from human and rabbit atherosclerotic lesions (lesion LDL) greatly resembles LDL that has been oxidatively modif...

Low Density Lipoprotein Oxidation and Its Pathobiological Significance

Daniel Steinberg · 1997 · Journal of Biological Chemistry · 1.6K citations

The fact that low density lipoprotein (LDL) 1The abbreviations used are: LDL, low density lipoprotein; SRA, scavenger receptor A; MM-LDL, minimally oxidized LDL; MCSF, macrophage colony-stimulating...

Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis

Ira Tabas, Kevin Jon Williams, Jan Borén · 2007 · Circulation · 1.4K citations

The key initiating process in atherogenesis is the subendothelial retention of apolipoprotein B–containing lipoproteins. Local biological responses to these retained lipoproteins, including a chron...

Atherosclerotic Plaque Progression and Vulnerability to Rupture

Renu Virmani, Frank D. Kolodgie, Allen Burke et al. · 2005 · Arteriosclerosis Thrombosis and Vascular Biology · 1.3K citations

Observational studies of necrotic core progression identify intraplaque hemorrhage as a critical factor in atherosclerotic plaque growth and destabilization. The rapid accumulation of erythrocyte m...

Reading Guide

Foundational Papers

Start with Witztum and Steinberg (1991, 2669 citations) for oxLDL atherogenic mechanisms, then Ylä-Herttuala et al. (1989, 1891 citations) for lesion evidence, followed by Steinberg (1997, 1635 citations) for pathobiology.

Recent Advances

Glass and Witztum (2001, 3030 citations) integrates oxLDL in atherosclerosis overview; Libby (2012, 3666 citations) links to inflammation; Febbraio et al. (2000, 1034 citations) validates CD36 role.

Core Methods

Oxidation via myeloperoxidase (Daugherty et al., 1994); scavenger uptake by CD36/SR-A (Febbraio et al., 2000); lesion extraction and immunoassays (Ylä-Herttuala et al., 1989).

How PapersFlow Helps You Research Oxidized LDL in Atherosclerosis

Discover & Search

Research Agent uses searchPapers and citationGraph to map oxLDL literature from Witztum and Steinberg (1991, 2669 citations), revealing clusters around scavenger receptors; exaSearch uncovers niche oxidation pathway papers, while findSimilarPapers expands from Ylä-Herttuala et al. (1989).

Analyze & Verify

Analysis Agent applies readPaperContent to extract oxLDL detection methods from Ylä-Herttuala et al. (1989), verifies foam cell data with CoVe against Glass and Witztum (2001), and runs PythonAnalysis for citation trend stats or lesion LDL oxidation metrics with GRADE scoring for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in CD36 targeting post-Febbraio et al. (2000); Writing Agent uses latexEditText, latexSyncCitations for review drafts, latexCompile for plaque diagrams via exportMermaid, enabling export of synthesized oxLDL pathway figures.

Use Cases

"Analyze citation trends of oxLDL scavenger receptor papers over 30 years"

Research Agent → searchPapers('oxLDL CD36 SR-A') → Analysis Agent → runPythonAnalysis(pandas on citation data) → matplotlib trend plot with statistical verification.

"Write LaTeX review on myeloperoxidase in oxLDL oxidation"

Research Agent → citationGraph(Daugherty 1994) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → formatted PDF section with synced references.

"Find code for simulating oxLDL uptake models from atherosclerosis papers"

Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → validated simulation code for macrophage foam cell kinetics.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ oxLDL papers: searchPapers → citationGraph → DeepScan with 7-step CoVe checkpoints verifying oxidation claims against Steinberg (1997). Theorizer generates hypotheses on MPO-CD36 interactions from Daugherty et al. (1994) and Febbraio et al. (2000), outputting Mermaid diagrams of proposed pathways.

Try Doxa for Oxidized LDL in Atherosclerosis Research

Frequently Asked Questions

What defines oxidized LDL in atherosclerosis?

Oxidized LDL is LDL modified by reactive oxygen species in the arterial wall, immunogenic and taken up by scavenger receptors like CD36 and SR-A, unlike native LDL via LDL receptors (Witztum and Steinberg, 1991).

What are key methods for detecting oxLDL?

Lesion LDL extraction shows oxidative modifications resembling in vitro oxLDL, with immunoreactivity to oxidation-specific antibodies; Ylä-Herttuala et al. (1989) used electrophoresis and immunoassays on human/rabbit plaques.

What are foundational papers?

Witztum and Steinberg (1991, 2669 citations) on oxLDL atherogenicity; Ylä-Herttuala et al. (1989, 1891 citations) detecting oxLDL in lesions; Steinberg (1997, 1635 citations) on pathobiological significance.

What open problems exist?

In vivo oxidation sources beyond MPO, precise CD36/SR-A contributions in humans, and effective oxLDL-targeted therapies despite preclinical data (Febbraio et al., 2000; Libby, 2012).